PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35381683-0	2022	(Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report).	Azacitidine	134-145	nucleophosmin 1	Homo sapiens	56-60	
22230298-3	2012	Numerous differentially expressed proteins were identified with MALDI-TOF/TOF-MS. Cyclophilin A, Catalase, Nucleophosmin and PCNA were decreased exclusively by azacitidine, TCP1 and hnRNP A2/B1 by both drugs; alpha-Enolase and Peroxiredoxin-1 by decitabine.	Azacitidine	160-171	nucleophosmin 1	Homo sapiens	107-120	
21750085-0	2011	Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.	Azacitidine	60-71	nucleophosmin 1	Homo sapiens	89-93	
19776758-0	2010	Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.	Azacitidine	69-82	nucleophosmin 1	Homo sapiens	45-49	
35063965-9	2022	In patients treated with venetoclax+azacitidine, CRc in patients with FLT3-ITD and FLT3-TKD was 63% and 77%, median OS was 9.9 and 19.2 months, and in co-mutated FLT3-ITD+NPM1, CRc was 70%, median DoR was not reached, and median OS was 9.1 months.	Azacitidine	36-47	nucleophosmin 1	Homo sapiens	171-175	
25643589-9	2015	Maintenance lenalidomide/azacitidine augmented the function of cytotoxic T lymphocytes, particularly in patients with NPM1 mutation.	Azacitidine	25-36	nucleophosmin 1	Homo sapiens	118-122	
25643589-10	2015	The lenalidomide/azacitidine maintenance combination was effective in suppressing residual DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A)-positive disease, resulting in sustained remission in patients with concurrent NPM1 mutation.	Azacitidine	17-28	nucleophosmin 1	Homo sapiens	223-227